Dana Elroy Wood

US Patent:

20100040610, Feb 18, 2010

Filed:

Nov 2, 2007

Appl. No.:

12/312383

Inventors:

Ayesha Sitlani - Metuchen NJ, US
Carl P. Sparrow - Westfield NJ, US
Shilpa Pandit - Edison NJ, US
Jon H. Condra - Doylestown PA, US
Dana D. Wood - Collegeville PA, US
Timothy S. Fisher - Plainsboro NJ, US

International Classification:

A61K 39/395
C07K 16/18
C07H 21/00
C12N 15/74
C12N 5/07
C12P 21/02
G01N 33/53
A61P 35/00

US Classification:

4241331, 5303873, 536 2353, 4353201, 435325, 435 696, 435 721

Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

US Patent:

20120082680, Apr 5, 2012

Filed:

Sep 23, 2011

Appl. No.:

13/242831

Inventors:

Ayesha Sitlani - Metuchen NJ, US
Carl P. Sparrow - Westfield NJ, US
Shilpa Pandit - Edison NJ, US
Jon H. Condra - Doylestown PA, US
Dana D. Wood - Collegeville PA, US
Timothy S. Fisher - Plainsboro NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/395
C12N 15/13
A61P 7/00
A61P 9/00
G01N 21/64
C12N 15/63
C12N 5/10
C12N 1/21
C12N 1/19
C12Q 1/02
C07K 16/40
A61P 3/00

US Classification:

4241581, 5303898, 536 2353, 4353201, 435338, 43525233, 43525231, 43525235, 4352542, 435 23, 435 71

Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

US Patent:

20140220027, Aug 7, 2014

Filed:

Apr 14, 2014

Appl. No.:

14/252621

Inventors:

- Rahway NJ, US
Rose M. Cubbon - Fanwood NJ, US
Holly A. Hammond - Telford PA, US
Laura Orsatti - Ponezia, IT
Shilpa Pandit - Edison NJ, US
Laurence B. Peterson - Westfield NJ, US
Joseph C. Santoro - Belle Mead NJ, US
Ayesha Sitlani - Metuchen MA, US
Dana D. Wood - Collegeville PA, US
Henryk Mach - Amber PA, US
Heidi Yoder Pixley - Glenside PA, US
Sonia M. Gregory - Charlottesville VA, US
Jeffrey T. Blue - Telford PA, US
Kevin Wang - San Francisco CA, US
Peizhi (Peter) Luo - Lansdale PA, US
Denise K. Nawrocki - Annandale NJ, US
Pingyu Zhong - Blue Bell PA, US
Feng Dong - Lansdale PA, US
Yan Li - San Jose CA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07K 16/40

US Classification:

4241391, 5303879, 536 2353, 435184, 4353201, 435 696, 43525233, 43525231, 43525235, 435331, 4352542

Abstract:

Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.